Nintedanib-d3
Based on 1 Customer Validation
Nintedanib-d3 (BIBF 1120-d3; Intedanib-d3) is the deuterated-labeled Nintedanib (HY-50904). Nintedanib is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease.
For research use only. We do not sell to patients.
- Purity : 99.78%
- CAS No.: 1624587-84-3
- Formula: C31H30D3N5O4
- Molecular Weight:542.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
|
VEGFR1 34 nM (IC50) |
VEGFR2 13 nM (IC50) |
VEGFR3 13 nM (IC50) |
PDGFRα 59 nM (IC50) |
PDGFRβ 65 nM (IC50) |
FGFR1 69 nM (IC50) |
FGFR2 37 nM (IC50) |
FGFR3 108 nM (IC50) |
Akt |
Caspase 3 |
IL-1β |
IL-6 |
TNF-α |
Product Details
-
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1624587-84-3
-
Unlabeled CAS 656247-17-5
-
Appearance Solid
-
Molecular Weight 542.64
-
Formula C31H30D3N5O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C([2H])([2H])[2H])CC4)=O)C=C3)/C5=CC=CC=C5)OC
-
Synonyms
BIBF 1120-d3; Intedanib-d3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (184.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8428 mL | 9.2142 mL | 18.4284 mL | 46.0711 mL |
| 5 mM | 0.3686 mL | 1.8428 mL | 3.6857 mL | 9.2142 mL | |
| 10 mM | 0.1843 mL | 0.9214 mL | 1.8428 mL | 4.6071 mL | |
| 15 mM | 0.1229 mL | 0.6143 mL | 1.2286 mL | 3.0714 mL | |
| 20 mM | 0.0921 mL | 0.4607 mL | 0.9214 mL | 2.3036 mL | |
| 25 mM | 0.0737 mL | 0.3686 mL | 0.7371 mL | 1.8428 mL | |
| 30 mM | 0.0614 mL | 0.3071 mL | 0.6143 mL | 1.5357 mL | |
| 40 mM | 0.0461 mL | 0.2304 mL | 0.4607 mL | 1.1518 mL | |
| 50 mM | 0.0369 mL | 0.1843 mL | 0.3686 mL | 0.9214 mL | |
| 60 mM | 0.0307 mL | 0.1536 mL | 0.3071 mL | 0.7679 mL | |
| 80 mM | 0.0230 mL | 0.1152 mL | 0.2304 mL | 0.5759 mL | |
| 100 mM | 0.0184 mL | 0.0921 mL | 0.1843 mL | 0.4607 mL |
Keywords
- Nintedanib-d3
- 1624587-84-3
- BIBF 1120-d3
- Intedanib-d3
- Isotope-Labeled Compounds
- PDGFR
- VEGFR
- FGFR
- Akt
- Caspase
- p38 MAPK
- Interleukin Related
- TNF Receptor
- Reactive Oxygen Species (ROS)
- Apoptosis
- Platelet-derived growth factor receptor
- Vascular endothelial growth factor receptor
- Fibroblast growth factor receptor
- PKB
- Protein kinase B
- IL
- Tumor Necrosis Factor Receptor
- TNFR
- CD8+ T cells
- FGFR1
- Flt-3
- Lck
- Lyn
- PDGFRα
- PI3K/Akt/mTOR
- Src
- VEGFR1
- pulmonary fibrosis
- Inhibitor
- inhibitor
- inhibit